Sugi Predict

Sugi Predict / Compounds / SCHEMBL1001104

SCHEMBL1001104

SCHEMBL1001104

O=S(=O)(O)c1ccccc1P(c1ccccc1S(=O)(=O)O)c1ccccc1S(=O)(=O)O.[Na].[Na].[Na]

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 3/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ MYC P01106 1/20 0.41
▸ TTR P02766 2/20 0.39
▸ POLB P06746 2/20 0.36
▸ CYP2D6 P10635 1/20 0.36
▸ FABP4 P15090 1/20 0.36
▸ CCNA2 P20248 1/20 0.36
▸ CDK2 P24941 1/20 0.36
▸ MAPK14 Q16539 1/20 0.36
▸ NR4A1 P22736 1/20 0.35
▸ LMNA P02545 1/20 0.34
▸ PGAM1 P18669 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ ALDH1A1 P00352 3/20 0.33
▸ HTR6 P50406 2/20 0.33
▸ TDP1 Q9NUW8 2/20 0.33
▸ GAA P10253 2/20 0.33
▸ CHAT P28329 1/20 0.33
▸ SNCA P37840 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8154480 1.00 TSHR (0.46) TSHRSMN1; SMN2MYCTTRPOLB
SCHEMBL30558761 0.98 MYC (0.42) TSHRSMN1; SMN2MYCTTRPOLB
SCHEMBL1006651 0.98 MYC (0.42) TSHRSMN1; SMN2MYCTTRPOLB
SCHEMBL476699 0.95 MYC (0.41) TSHRSMN1; SMN2MYCTTRPOLB
SCHEMBL8011562 0.95 MYC (0.41) TSHRSMN1; SMN2MYCTTRPOLB
SCHEMBL19861003 0.88 AURKA (0.38) TSHRSMN1; SMN2MYCTTRPOLB
SCHEMBL8145544 0.88 TSHR (0.45) TSHRSMN1; SMN2MYCTTRPOLB
SCHEMBL16075637 0.86 MYC (0.43) TSHRSMN1; SMN2MYCTTRPOLB
SCHEMBL1823611 0.85 TDP1 (0.42) TSHRSMN1; SMN2MYCTTRPOLB
SCHEMBL29714465 0.85 TDP1 (0.42) TSHRSMN1; SMN2MYCTTRPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11214779-B2 Activatable CRISPR/CAS9 for spatial and temporal control of genome editing University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2022-01-04 — — US disclosed
US-20180073002-A1 ACTIVATABLE CRISPR/CAS9 FOR SPATIAL AND TEMPORAL CONTROL OF GENOME EDITING University of Pittsburgh - of the Commonwealth Sys tem of Higher Education (US) 2018-03-15 — — US disclosed
EP-3280690-A1 BUTADIENE TELOMERIZATION CATALYST AND PREPARATION THEREOF Dow Global Technologies LLC (US) 2018-02-14 — — EP disclosed
WO-2016164797-A1 ACTIVATABLE CRISPR/CAS9 FOR SPATIAL AND TEMPORAL CONTROL OF GENOME EDITING UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2016-10-13 — — WO disclosed
WO-2016164258-A1 BUTADIENE TELOMERIZATION CATALYST AND PREPARATION THEREOF DOW GLOBAL TECHNOLOGIES LLC (US) 2016-10-13 — — WO disclosed
EP-2451792-A2 PROCESS FOR SUBSTITUTED 3-AMINO-5-OXO-4,5-DIHYDRO-[1,2,4]TRIAZINES OSI Pharmaceuticals, LLC (US) 2012-05-16 — — EP disclosed
EP-2358371-A1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN Merck Sharp & Dohme Corp. (US) 2011-08-24 — — EP disclosed
WO-2011005909-A2 PROCESS FOR SUBSTITUTED 3-AMINO-5-OXO-4,5-DIHYDRO-[1,2,4]TRIAZINES OSI PHARMACEUTICALS, INC. (US) 2011-01-13 — — WO disclosed
EP-2215048-A1 P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN Merck Sharp & Dohme Corp. (US) 2010-08-11 — — EP disclosed
EP-2215049-A1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN Merck Sharp & Dohme Corp. (US) 2010-08-11 — — EP disclosed
WO-2010051188-A1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK SHARP & DOHME CORP. (US) 2010-05-06 — — WO disclosed
WO-2009058299-A1 P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK & CO., INC. (US) 2009-05-07 — — WO disclosed
WO-2009058298-A1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK & CO., INC. (US) 2009-05-07 — — WO disclosed
EP-1638969-A2 CGRP RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 2006-03-29 — — EP disclosed
WO-2004092166-A2 CGRP RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2004-10-28 — — WO disclosed
EP-1461373-A1 POLYMERIC COMPOSITIONS AND USES THEREFORE SUMITOMO BAKELITE CO., LTD. (JP) 2004-09-29 — — EP disclosed
WO-2004035636-A2 POLYMERIZED CYCLOOLEFINS USING TRANSITION METAL CATALYST AND END PRODUCTS THEREOF PROMERUS, LLC (US) 2004-04-29 — — WO disclosed
WO-2003050158-A1 POLYMERIC COMPOSITIONS AND USES THEREFOR SUMITOMO BAKELITE CO., LTD. (US) 2003-06-19 — — WO disclosed
EP-1307493-A2 POLYMERIC COMPOSITIONS FOR FORMING OPTICAL WAVEGUIDES; OPTICAL WAVEGUIDES FORMED THEREFROM; AND METHODS FOR MAKING SAME Goodrich Corporation (US) 2003-05-07 — — EP disclosed
WO-2002010231-A2 POLYMERIC COMPOSITIONS FOR FORMING OPTICAL WAVEGUIDES; OPTICAL WAVEGUIDES FORMED THEREFROM; AND METHODS FOR MAKING SAME GOODRICH CORPORATION (US) 2002-02-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11214779-B2 Activatable CRISPR/CAS9 for spatial and temporal control of genome editing KARS1, GDA, ZFR TSHR 4281/4885SMN1; SMN2 3566/4885MYC 23/4885
US-20180073002-A1 ACTIVATABLE CRISPR/CAS9 FOR SPATIAL AND TEMPORAL CONTROL OF GENOME EDITING KARS1, GDA, ZFR TSHR 4281/4885SMN1; SMN2 3566/4885MYC 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.